Genetic Technologies (GENE) has released an update.
Genetic Technologies Limited, a pioneer in genomics-based testing, has announced obtaining a $600k short-term loan from Radium Capital, secured against its expected R&D Tax Incentive refund. This financial boost is intended for additional working capital and will incur a monthly interest of 1.33%. The loan aligns with the company’s efforts to improve health outcomes worldwide through its advanced cancer predictive testing and risk assessment tools.
For further insights into GENE stock, check out TipRanks’ Stock Analysis page.
